Jennifer L. Crombie

Dana-Farber Cancer Institute — United States

Medicine · Health Sciences

23h-index2.0kcitations167works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(76), CAR-T cell therapy research(60), Chronic Lymphocytic Leukemia Research(55), Viral-associated cancers and disorders(11), CNS Lymphoma Diagnosis and Treatment(11)

Publications167 total

Outpatient Versus Inpatient Management of Grade 1 Cytokine Release Syndrome in Follicular Lymphoma Patients Receiving Bispecific Antibodies: A Cubic Study
Transplantation and Cellular Therapy·2026Open Access
Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study
Blood Advances·2026Open Access
Could treatment modification based on early response assessment improve results in DLBCL?
Hematology·2025Open Access
Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma
Blood·2025Open Access
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial
Blood·2025
Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab
Blood·2025Open Access
Real-world implementation of bispecific antibody delivery in community oncology: Overcoming operational barriers through partnerships & interprofessional education
Blood·2025Open Access
Relapsed diffuse large B-cell lymphoma is shaped by molecular subtypes and genomic alterations
Blood·2025Open Access
Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry
Blood·2025Open Access
Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial
Blood·2025Open Access
Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab
Blood·2025Open Access
Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study
Blood·2025Open Access
Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study
Blood·2025Open Access
Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium
Blood·2025Open Access
A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)
Blood·2025
Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas
Blood·2025Open Access
Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma
Blood·2025
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)
Blood·2025· 1 citedOpen Access
Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
HemaSphere·2025Open Access
A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma
Blood Advances·2025Open Access
page 1 of 9Next →

Frequent Co-authors

Philippe Armand(25), Ann S. LaCasce(21), David C. Fisher(19), Caron A. Jacobson(19), Matthew S. Davids(18), Jennifer R. Brown(16), Austin I. Kim(15), Reid W. Merryman(12), Samuel Y. Ng(12), Robert Redd(11), Eric D. Jacobsen(10), Jon Arnason(10), Alex F. Herrera(9), Svitlana Tyekucheva(9), Josie Montegaard(8), Yi‐Bin Chen(7), Robin Joyce(7), Oreofe O. Odejide(7), Erin Jeter(6), Parastoo B. Dahi(6)